Oric Pharmaceuticals, Inc. — Form 10-Q
Filed August 3, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 8/100
What the filing says
This is a standard Q2 2026 quarterly report filing for Oric Pharmaceuticals (market cap ~$862M), accepted August 3, 2026, covering the period ending June 30, 2026. The filing header and document metadata are present, but the actual financial statements, MD&A, and business developments are not included in the provided text excerpt. No specific counterparties, dollar amounts, share counts, or material transactions are disclosed in this excerpt.
Why this rating
Routine quarterly disclosure filing with no extractable operational or financial detail provided in text excerpt; cannot assess materiality without full 10-Q content.
See more from August 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.